

Special Issue

Treatment of Orthopoxvirus Infections

Message from the Guest Editor

Smallpox remains the only human disease completely eradicated through a successful vaccination campaign. As routine smallpox vaccination of the general public was discontinued, the majority of the current population are naive to orthopoxvirus infection. Human orthopoxvirus infections are predominantly caused by monkeypox virus in Africa, cowpoxvirus in Europe, vaccinia virus in South America, and buffalopoxvirus in Asia. Due to the smallpox adverse effects caused by the replication of the competitive vaccinia virus in contraindicated individuals, a safer non-replicative vaccine was recently approved by the Food and Drug Administration (FDA). TPOXX was approved for smallpox treatments by FDA recently. There is a need for additional antivirals that target different steps in the orthopoxvirus lifecycle. Similarly, prophylactic treatment with antibodies against orthopoxviruses is needed. We hope this Special Issue will cover several of these important topics for treatment of orthopoxvirus infections.

Guest Editor

Dr. Panayampalli Subbian Satheshkumar
Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA

Deadline for manuscript submissions

closed (15 February 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/40953

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).